Header Logo

Connection

EUGENIE S KLEINERMAN to Bone Neoplasms

Back to Details
This is a "connection" page, showing publications EUGENIE S KLEINERMAN has written about Bone Neoplasms.
EUGENIE S KLEINERMAN
Connection Strength
6.669
Bone Neoplasms
  1. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology. 2020; 9(1):1747677.
    View in: PubMed
    Score: 0.298
  2. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Adv Exp Med Biol. 2020; 1258:177-187.
    View in: PubMed
    Score: 0.293
  3. Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Mol Cancer Ther. 2018 06; 17(6):1315-1323.
    View in: PubMed
    Score: 0.259
  4. Maximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps? Lancet Oncol. 2016 10; 17(10):1340-1342.
    View in: PubMed
    Score: 0.232
  5. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. Adv Exp Med Biol. 2014; 804:203-17.
    View in: PubMed
    Score: 0.193
  6. Osteosarcoma: the state of affairs dictates a change. What do we know? Adv Exp Med Biol. 2014; 804:vii-viii.
    View in: PubMed
    Score: 0.193
  7. Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. BMC Cancer. 2013 Oct 26; 13:500.
    View in: PubMed
    Score: 0.191
  8. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer. 2014 Apr; 61(4):618-26.
    View in: PubMed
    Score: 0.190
  9. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets. 2013 May; 13(4):411-22.
    View in: PubMed
    Score: 0.184
  10. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Pediatr Blood Cancer. 2013 Apr; 60(4):575-9.
    View in: PubMed
    Score: 0.180
  11. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2012 Feb 15; 72(4):908-16.
    View in: PubMed
    Score: 0.168
  12. Genetically modified T cells targeting interleukin-11 receptor a-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012 Jan 01; 72(1):271-81.
    View in: PubMed
    Score: 0.166
  13. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 2010 Aug; 23(4):189-96.
    View in: PubMed
    Score: 0.152
  14. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res. 2010 Aug 01; 16(15):4024-30.
    View in: PubMed
    Score: 0.151
  15. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. Cancer Res. 2010 Feb 15; 70(4):1334-43.
    View in: PubMed
    Score: 0.147
  16. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res. 2009; 152:497-508.
    View in: PubMed
    Score: 0.137
  17. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther. 2008 Jul; 7(7):1807-16.
    View in: PubMed
    Score: 0.132
  18. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol. 2008 Jul; 30(7):507-12.
    View in: PubMed
    Score: 0.132
  19. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res. 2008 Jun; 6(6):929-36.
    View in: PubMed
    Score: 0.131
  20. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis. 2008; 11(3):257-67.
    View in: PubMed
    Score: 0.129
  21. The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells. Mol Cancer Res. 2008 Jan; 6(1):119-26.
    View in: PubMed
    Score: 0.127
  22. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 2008; 7(2):89-97.
    View in: PubMed
    Score: 0.127
  23. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res. 2007 Nov; 5(11):1125-32.
    View in: PubMed
    Score: 0.126
  24. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer. 2007 Oct 01; 110(7):1568-77.
    View in: PubMed
    Score: 0.125
  25. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007 Oct; 5(10):991-9.
    View in: PubMed
    Score: 0.125
  26. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4503-10.
    View in: PubMed
    Score: 0.124
  27. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma. Cancer Gene Ther. 2006 Oct; 13(10):948-57.
    View in: PubMed
    Score: 0.114
  28. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer. 2006 Mar 15; 106(6):1382-8.
    View in: PubMed
    Score: 0.112
  29. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res. 2005 Dec; 3(12):685-91.
    View in: PubMed
    Score: 0.110
  30. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol. 2005 Nov; 27(11):611-5.
    View in: PubMed
    Score: 0.110
  31. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005 Oct 15; 104(8):1713-20.
    View in: PubMed
    Score: 0.109
  32. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005 Sep 01; 116(3):458-63.
    View in: PubMed
    Score: 0.108
  33. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res. 2005 Feb 15; 65(4):1124-8.
    View in: PubMed
    Score: 0.104
  34. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis. 2004; 21(8):747-53.
    View in: PubMed
    Score: 0.097
  35. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 2002 Mar; 9(3):260-6.
    View in: PubMed
    Score: 0.085
  36. Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity. Cancer Med. 2021 11; 10(21):7572-7584.
    View in: PubMed
    Score: 0.082
  37. Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features. Apoptosis. 2021 08; 26(7-8):447-459.
    View in: PubMed
    Score: 0.081
  38. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res. 2001 May 15; 61(10):4066-71.
    View in: PubMed
    Score: 0.080
  39. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer. 2021 04 15; 148(8):1928-1937.
    View in: PubMed
    Score: 0.078
  40. Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma. Pediatr Blood Cancer. 2019 09; 66(9):e27835.
    View in: PubMed
    Score: 0.070
  41. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
    View in: PubMed
    Score: 0.069
  42. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res. 1997 Oct; 3(10):1721-9.
    View in: PubMed
    Score: 0.063
  43. BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proc Natl Acad Sci U S A. 2017 07 25; 114(30):8065-8070.
    View in: PubMed
    Score: 0.062
  44. Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.059
  45. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995 Aug; 9(4):927-38.
    View in: PubMed
    Score: 0.054
  46. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995 Apr; 18(2):93-9.
    View in: PubMed
    Score: 0.053
  47. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014 Aug 15; 20(16):4200-9.
    View in: PubMed
    Score: 0.049
  48. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 2014 Feb; 61(2):238-44.
    View in: PubMed
    Score: 0.047
  49. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:101-7.
    View in: PubMed
    Score: 0.045
  50. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood. 2011 Jan 13; 117(2):719-26.
    View in: PubMed
    Score: 0.039
  51. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv. 2010 Aug; 23(4):197-206.
    View in: PubMed
    Score: 0.038
  52. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15; 115(22):5339-48.
    View in: PubMed
    Score: 0.036
  53. Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo. 2009 Nov-Dec; 23(6):903-9.
    View in: PubMed
    Score: 0.036
  54. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 01; 26(4):633-8.
    View in: PubMed
    Score: 0.032
  55. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol Cancer. 2008 Jan 23; 7:9.
    View in: PubMed
    Score: 0.032
  56. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol. 2007 Dec; 29(12):815-21.
    View in: PubMed
    Score: 0.032
  57. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20; 23(9):2004-11.
    View in: PubMed
    Score: 0.026
  58. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res. 2004 Dec 01; 10(23):8114-9.
    View in: PubMed
    Score: 0.026
  59. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15; 9(15):5442-53.
    View in: PubMed
    Score: 0.024
  60. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001 Aug; 15(4):723-40, ix.
    View in: PubMed
    Score: 0.020
  61. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res. 2000 Sep; 6(9):3713-8.
    View in: PubMed
    Score: 0.019
  62. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res. 2000 Jul; 6(7):2876-80.
    View in: PubMed
    Score: 0.019
  63. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells. J Immunother Cancer. 2020 04; 8(1).
    View in: PubMed
    Score: 0.019
  64. Osteosarcoma metastatic to the pancreas in young patients. Clin Radiol. 1996 Apr; 51(4):293-4.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.